ASHLEY SKAGGS: Open Payments
NPI 1790925758 · BAY ST LOUIS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$662 in 41 payments from 9 companies in 2025. Trend: 2023 $791 · 2024 $887 · 2025 $662
Food & beverage: $662
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $340 |
| Novartis Pharmaceuticals Corporation | 3 | $70 |
| Lilly USA, LLC | 4 | $63 |
| Novo Nordisk Inc | 3 | $53 |
| Viatris Specialty LLC | 2 | $44 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| ABBVIE INC. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Amgen Inc. | 1 | $17 |
Products named: CAPLYTA, LEQVIO, MOUNJARO, YUPELRI, UBRELVY, Wegovy, GEMTESA, EVENITY.
Industry payments across MS — which companies pay providers there.
